Erenumab

What is Erenumab?[edit | edit source]

Erenumab (Aimovig), is a calcitonin gene-related peptide receptor antagonist.

Aimovig Autoinjector

calcitonin gene related peptide

Erenumab (Aimovig), is indicated for the preventive treatment of migraine in adults.

It binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function thus prevent migraine attacks.

Aimovig is contraindicated in patients with serious hypersensitivity to erenumab-aooe.

The United States Food and Drug Administration (FDA) approved the medication for the preventive treatment of migraine in adults on May 17, 2018.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Recommended dosage: Recommended dosage is 70 mg once monthly; some patients may benefit from a dosage of 140 mg once monthly.

Administration:

The prefilled forms has dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex.
Prior to subcutaneous administration, allow Aimovig to sit at room temperature for at least 30 minutes protected from direct sunlight
Do not warm by using a heat source such as hot water or a microwave.
Do not shake the product.
Do not use if the solution is cloudy or discolored or contains flakes or particles.
Administer Aimovig in the abdomen, thigh, or upper arm subcutaneously. Do not inject into areas where the skin is tender, bruised, red, or hard.

The most common side effects of this medicine include:

Less common,but serious side effects may include:

Provide guidance to patients and caregivers on proper subcutaneous administration technique, including aseptic technique, and how to use the single-dose prefilled autoinjector or single-dose prefilled syringe. Instruct patients and/or caregivers to read and follow the Instructions for Use each time they use Aimovig.
Advise patients to let Aimovig sit at room temperature for at least 30 minutes prior to administration.
Advise patients to seek immediate medical attention if they experience any symptoms of serious or severe hypersensitivity reactions.
Advise patients that constipation with serious complications can occur with Aimovig and that they should contact their healthcare providers if they experience severe constipation.
Advise patients that development of hypertension and worsening of pre-existing hypertension can occur with Aimovig and that they should contact their healthcare providers if they experience elevation in their blood pressure.
Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Aimovig during pregnancy.
It is not known if Aimovig passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while using Aimovig.
Erenumab therapy has not been associated with serum enzyme elevations during therapy nor has it been implicated in cases of clinically apparent drug induced liver injury with jaundice.

In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Overdose related information is also available online at poisonhelp.org/help.
In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.
seek emergency medical care

There are no adequate data on the developmental risk associated with the use of Aimovig in pregnant women.
There is a pregnancy registry for women who take Aimovig. The purpose of this registry is to collect information about your health and your baby's health. You may enroll yourself by calling 1-833-244-4083 or visiting https://www.genesispregnancyregistry.com/. Or you may talk to your doctor about how you can take part in this registry.

Erenumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.